Duopharma Biotech Bhd - Asset Resilience Ratio

Latest as of December 2025: 20.08%

Duopharma Biotech Bhd (7148) has an Asset Resilience Ratio of 20.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Duopharma Biotech Bhd (7148) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

RM290.87 Million
≈ $73.03 Million USD Cash + Short-term Investments

Total Assets

RM1.45 Billion
≈ $363.62 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Duopharma Biotech Bhd's Asset Resilience Ratio has changed over time. See Duopharma Biotech Bhd balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Duopharma Biotech Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 7148 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents RM290.87 Million 20.08%
Short-term Investments RM0.00 0%
Total Liquid Assets RM290.87 Million 20.08%

Asset Resilience Insights

  • Good Liquidity Position: Duopharma Biotech Bhd maintains a healthy 20.08% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Duopharma Biotech Bhd Industry Peers by Asset Resilience Ratio

Compare Duopharma Biotech Bhd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Aurobindo Pharma Limited
NSE:AUROPHARMA
Drug Manufacturers - Specialty & Generic 1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Xeris Pharmaceuticals Inc
NASDAQ:XERS
Drug Manufacturers - Specialty & Generic 0.00%
Procter & Gamble Health Limited
NSE:PGHL
Drug Manufacturers - Specialty & Generic 33.01%

Annual Asset Resilience Ratio for Duopharma Biotech Bhd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Duopharma Biotech Bhd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 11.71% RM161.25 Million
≈ $40.48 Million
RM1.38 Billion
≈ $345.72 Million
-12.35pp
2023-12-31 24.06% RM323.59 Million
≈ $81.24 Million
RM1.35 Billion
≈ $337.72 Million
+17.71pp
2022-12-31 6.34% RM77.49 Million
≈ $19.46 Million
RM1.22 Billion
≈ $306.78 Million
+3.73pp
2021-12-31 2.62% RM30.45 Million
≈ $7.64 Million
RM1.16 Billion
≈ $292.27 Million
-2.37pp
2020-12-31 4.99% RM52.81 Million
≈ $13.26 Million
RM1.06 Billion
≈ $265.74 Million
+0.46pp
2019-12-31 4.53% RM41.67 Million
≈ $10.46 Million
RM919.80 Million
≈ $230.93 Million
+1.94pp
2018-12-31 2.59% RM21.70 Million
≈ $5.45 Million
RM836.38 Million
≈ $209.99 Million
-4.33pp
2017-12-31 6.93% RM48.86 Million
≈ $12.27 Million
RM705.24 Million
≈ $177.06 Million
-5.84pp
2016-12-31 12.77% RM84.48 Million
≈ $21.21 Million
RM661.46 Million
≈ $166.07 Million
--
pp = percentage points

About Duopharma Biotech Bhd

KLSE:7148 Malaysia Drug Manufacturers - Specialty & Generic
Market Cap
$297.06 Million
RM1.18 Billion MYR
Market Cap Rank
#15017 Global
#175 in Malaysia
Share Price
RM1.23
Change (1 day)
+0.00%
52-Week Range
RM1.21 - RM1.55
All Time High
RM2.86
About

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more